Latest & greatest articles for adalimumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adalimumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adalimumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adalimumab

101. Adalimumab (Humira) - in combination with methotrexate, for the treatment of active polyarticular juvenile idiopathic arthritis

Adalimumab (Humira) - in combination with methotrexate, for the treatment of active polyarticular juvenile idiopathic arthritis All Wales Medicines Strategy Group (AWMSG) - adalimumab (Humira) | | Appraisal information Search and reports adalimumab (Humira®) Reference No. 1977 Publication date: 15/08/2013 Appraisal information adalimumab (Humira®) 40 mg solution for injection Company: AbbVie Ltd BNF category: Musculoskeletal and joint diseases NMG meeting date: 19/06/2013 AWMSG meeting date: 17 (...) /07/2013 Submission Type: Limited Submission Status: Superseded Advice No: 2113 Ratification by Welsh Government: 14/08/2013 Current Progress Submission received NMG meeting AWMSG meeting Ratification by Welsh Government AWMSG advice AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA373) NICE GUIDANCE ISSUED DECEMBER 2015 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Adalimumab (Humira®) is recommended as an option

All Wales Medicines Strategy Group2013

102. Adalimumab (Humira) - ankylosing spondylitis

Adalimumab (Humira) - ankylosing spondylitis All Wales Medicines Strategy Group (AWMSG) - adalimumab (Humira) | | Appraisal information Search and reports adalimumab (Humira®) Reference No. 1381 Publication date: 31/07/2013 Appraisal information adalimumab (Humira®) 40 mg solution for injection Company: AbbVie Ltd BNF category: Musculoskeletal and joint diseases NMG meeting date: 15/05/2013 AWMSG meeting date: 12/06/2013 Submission Type: Full Submission Status: Superseded Advice No: 1513 (...) Ratification by Welsh Government: 29/07/2013 Current Progress Submission received NMG meeting AWMSG meeting Ratification by Welsh Government AWMSG advice AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA383) NICE GUIDANCE ISSUED FEBRUARY 2016 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Adalimumab (Humira®) is recommended for use within NHS Wales for the treatment of adults with severe axial spondyloarthritis without

All Wales Medicines Strategy Group2013

103. Adalimumab (Humira) - for the treatment of severe active Crohn's disease in paediatric patients

Adalimumab (Humira) - for the treatment of severe active Crohn's disease in paediatric patients Published 08 July 2013 Product Update: adalimumab 40mg solution for injection in a single-use pre-filled syringe, pre- filled pen and a 40mg/0.8mL paediatric vial (Humira®) (No: 880/13) AbbVie Ltd 07 June 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland (...) . The advice is summarised as follows: ADVICE: following an abbreviated submission adalimumab (Humira®) is accepted for restricted use within NHS Scotland. Indication under review: is indicated for the treatment of severe active Crohn's disease in paediatric patients (6 to 17 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy, a corticosteroid, and an immunomodulator, or who are intolerant to or have contraindications for such therapies. SMC

Scottish Medicines Consortium2013

104. Adalimumab (Humira) - in combination with methotrexate for the treatment of active polyarticular juvenile idiopathic arthritis

Adalimumab (Humira) - in combination with methotrexate for the treatment of active polyarticular juvenile idiopathic arthritis Published 08 July 2013 Product Update: adalimumab 40mg solution for injection in pre-filled syringe or pen, 40mg/0.8ml solution for injection vial for paediatric use (Humira®) (No:881/13) AbbVie Ltd 07 June 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs (...) ) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission adalimumab (Humira®) solution for injection is accepted for restricted use within NHS Scotland. Indication under review: in combination with methotrexate for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 2 to 17 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Adalimumab can be

Scottish Medicines Consortium2013

106. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind,

Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, 23434570 2014 02 28 2014 04 29 2015 11 19 1468-2060 73 4 2014 Apr Annals of the rheumatic diseases Ann. Rheum. Dis. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid (...) arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. 654-61 10.1136/annrheumdis-2012-202735 An investigator-initiated, double-blinded, placebo-controlled, treat-to-target protocol (Clinical Trials:NCT00660647) studied whether adalimumab added to methotrexate and intra-articular triamcinolone as first-line treatment in early rheumatoid arthritis (ERA) increased the frequency

EvidenceUpdates2013

107. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. BACKGROUND: Roughly a third of patients with rheumatoid arthritis treated with biological treatments receive them as monotherapy. Tocilizumab--an inhibitor of interleukin 6 receptor signalling--has been studied as monotherapy in several clinical trials. We assessed the efficacy and safety of tocilizumab monotherapy compared with adalimumab (...) mg per kg bodyweight intravenously every 4 weeks plus placebo subcutaneously every 2 weeks or adalimumab 40 mg subcutaneously every 2 weeks plus placebo intravenously every 4 weeks for 24 weeks. Investigators, patients, and sponsor personnel were masked to assignment. The primary endpoint was change in disease activity score using 28 joints (DAS28) from baseline to week 24. This trial is registered with ClinicalTrials.gov, number NCT01119859 . FINDINGS: We screened 452 patients and enrolled 326

Lancet2013

108. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study

Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study 23316080 2014 02 05 2014 04 28 2016 12 15 1468-2060 73 3 2014 Mar Annals of the rheumatic diseases Ann. Rheum. Dis. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. 536-43 10.1136/annrheumdis-2012 (...) -202433 To evaluate the efficacy and safety of adalimumab+methotrexate (MTX) in Japanese patients with early rheumatoid arthritis (RA) who had not previously received MTX or biologics. This randomised, double-blind, placebo-controlled, multicentre study evaluated adalimumab 40 mg every other week+MTX 6-8 mg every week versus MTX 6-8 mg every week alone for 26 weeks in patients with RA (≤2-year duration). The primary endpoint was inhibition of radiographic progression (change (Δ) from baseline

EvidenceUpdates2013 Full Text: Link to full Text with Trip Pro

110. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis

Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis Soini EJ, Hallinen TA, Puolakka K, Vihervaara V, Kauppi MJ Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-utility of adalimumab, etanercept, and tocilizumab, as first biologic treatments for moderate-to-severe rheumatoid arthritis, after the failure of one or more traditional disease

NHS Economic Evaluation Database.2013

111. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. 23515142 2013 05 06 2013 05 30 2016 11 25 1474-547X 381 9877 2013 May 04 Lancet (London, England) Lancet Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. 1541-50 10.1016/S0140-6736(13)60250-0 S0140-6736(13)60250-0 Roughly a third (...) of patients with rheumatoid arthritis treated with biological treatments receive them as monotherapy. Tocilizumab--an inhibitor of interleukin 6 receptor signalling--has been studied as monotherapy in several clinical trials. We assessed the efficacy and safety of tocilizumab monotherapy compared with adalimumab monotherapy for patients with rheumatoid arthritis. We did this randomised, double-blind, parallel-group, phase 4 superiority study in 76 centres in 15 countries in North and South America

Lancet2013

113. Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis: a review of the comparative clinical efficacy, safety and cost effectiveness

Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis: a review of the comparative clinical efficacy, safety and cost effectiveness Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis: a review of the comparative clinical efficacy, safety and cost effectiveness Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis: a review of the comparative clinical efficacy, safety and cost (...) effectiveness CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis: a review of the comparative clinical efficacy, safety and cost effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions Infliximab

Health Technology Assessment (HTA) Database.2012

114. Adalimumab (Humira®)

Adalimumab (Humira®) Adalimumab (Humira®) Adalimumab (Humira®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Adalimumab (Humira®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat (...) Assessment Report Advice No. 0812. 2012 Authors' conclusions Adalimumab (Humira®) in combination with methotrexate is recommended as an option for use within NHS Wales for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 4 to 17 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs. Adalimumab (Humira®) can be given as monotherapy in case of intolerance to methotrexate or when continued treatment

Health Technology Assessment (HTA) Database.2012

116. Adalimumab (Humira) - treatment of moderately to severely active ulcerative colitis

Adalimumab (Humira) - treatment of moderately to severely active ulcerative colitis Published 09 July 2012 Statement of Advice: adalimumab (Humira ®) Pre-filled Pen, Pre-filled Syringe and Vial (No: 800/12) Abbott Laboratories Limited 08 June 2012 ADVICE: in the absence of a submission from the holder of the marketing authorisation adalimumab (Humira ®) is not recommended for use within NHS Scotland. Indication under review: treatment of moderately to severely active ulcerative colitis in adult

Scottish Medicines Consortium2012

117. Adalimumab induces and maintains mucosal healing in patients with Crohn`s disease: data from the EXTEND trial

Adalimumab induces and maintains mucosal healing in patients with Crohn`s disease: data from the EXTEND trial 22326435 2012 04 24 2012 06 18 2015 11 19 1528-0012 142 5 2012 May Gastroenterology Gastroenterology Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. 1102-1111.e2 10.1053/j.gastro.2012.01.035 We investigated the efficacy of adalimumab for inducing and maintaining mucosal healing in patients with Crohn's disease (CD (...) ). A randomized, double-blind, placebo-controlled trial (extend the safety and efficacy of adalimumab through endoscopic healing [EXTEND]) evaluated adalimumab for induction and maintenance of mucosal healing in 135 adults with moderate to severe ileocolonic CD. The baseline degree of mucosal ulceration was documented by ileocolonoscopy. All patients received induction therapy (subcutaneous adalimumab 160/80 mg at weeks 0/2). At week 4, patients were randomly assigned to groups given 40 mg adalimumab

EvidenceUpdates2012

118. Switch to adalimumab in patients with Crohn`s disease controlled by maintenance infliximab: prospective randomised SWITCH trial

Switch to adalimumab in patients with Crohn`s disease controlled by maintenance infliximab: prospective randomised SWITCH trial 21948942 2011 12 26 2012 02 16 2015 11 19 1468-3288 61 2 2012 Feb Gut Gut Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. 229-34 10.1136/gutjnl-2011-300755 Elective switching between anti-tumour necrosis factor (TNF) agents not necessarily dictated by efficacy or tolerability occurs (...) in clinical practice. A study was undertaken to evaluate prospectively the impact of elective switching of patients with Crohn's disease well controlled with intravenous infliximab to subcutaneous adalimumab in a controlled trial. An open-label randomised single-centre trial recruited 73 patients with ongoing response to at least 6 months of scheduled maintenance infliximab. Patients were randomised to continue intravenous 5 mg/kg infliximab or to switch to subcutaneous adalimumab 80 mg at baseline

EvidenceUpdates2012

119. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs 21952978 2012 02 29 2012 07 10 2015 11 19 1529-0131 64 3 2012 Mar Arthritis and rheumatism Arthritis Rheum. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid (...) arthritis with an inadequate response to disease-modifying antirheumatic drugs. 617-29 10.1002/art.33383 To compare the efficacy, safety, and tolerability of 5 doses of oral tofacitinib (CP-690,550) or adalimumab monotherapy with placebo for the treatment of active rheumatoid arthritis (RA) in patients with an inadequate response to disease-modifying antirheumatic drugs. In this 24-week, double-blind, phase IIb study, patients with RA (n = 384) were randomized to receive placebo, tofacitinib at 1, 3, 5

EvidenceUpdates2012

120. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.

Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. 22873531 2012 08 09 2012 08 27 2015 11 19 1533-4406 367 6 2012 Aug 09 The New England journal of medicine N. Engl. J. Med. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. 508-19 10.1056/NEJMoa1112072 Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being investigated for the treatment of rheumatoid arthritis. In this 12-month, phase 3 trial, 717 patients who were receiving stable doses (...) of methotrexate were randomly assigned to 5 mg of tofacitinib twice daily, 10 mg of tofacitinib twice daily, 40 mg of adalimumab once every 2 weeks, or placebo. At month 3, patients in the placebo group who did not have a 20% reduction from baseline in the number of swollen and tender joints were switched in a blinded fashion to either 5 mg or 10 mg of tofacitinib twice daily; at month 6, all patients still receiving placebo were switched to tofacitinib in a blinded fashion. The three primary outcome measures

NEJM2012